Q32 BIO INC (QTTB) Stock Price, Quote, News and Overview
NASDAQ:QTTB - Nasdaq - US7469641051 - Common Stock - Currency: USD
QTTB Quote, Performance and Key Statistics
1.64
+0.08 (+5.13%)
The current stock price of QTTB is 1.64 USD. In the past month the price increased by 2.5%. In the past year, price decreased by -93.59%.
QTTB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.33 | 351.09B | ||
| AMGN | AMGEN INC | 13.55 | 151.20B | ||
| GILD | GILEAD SCIENCES INC | 13.4 | 129.08B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1728.1 | 128.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.67 | 65.39B | ||
| ARGX | ARGENX SE - ADR | 341.93 | 39.67B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.74B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.57B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.23B | ||
| NTRA | NATERA INC | N/A | 21.18B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.72B | ||
| BIIB | BIOGEN INC | 7.81 | 18.10B |
Related stock screener links
About QTTB
Company Profile
Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts and currently employs 42 full-time employees. The company went IPO on 2018-03-28. The company focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). The company has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.
Company Info
Q32 BIO INC
830 Winter Street
Waltham MASSACHUSETTS US
Employees: 42
Phone: 17819990232
Q32 BIO INC / QTTB FAQ
What is the stock price of Q32 BIO INC today?
The current stock price of QTTB is 1.64 USD. The price increased by 5.13% in the last trading session.
What is the ticker symbol for Q32 BIO INC stock?
The exchange symbol of Q32 BIO INC is QTTB and it is listed on the Nasdaq exchange.
On which exchange is QTTB stock listed?
QTTB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Q32 BIO INC stock?
10 analysts have analysed QTTB and the average price target is 11.48 USD. This implies a price increase of 599.7% is expected in the next year compared to the current price of 1.64. Check the Q32 BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Q32 BIO INC worth?
Q32 BIO INC (QTTB) has a market capitalization of 20.01M USD. This makes QTTB a Nano Cap stock.
How many employees does Q32 BIO INC have?
Q32 BIO INC (QTTB) currently has 42 employees.
What are the support and resistance levels for Q32 BIO INC (QTTB) stock?
Q32 BIO INC (QTTB) has a support level at 1.58 and a resistance level at 1.87. Check the full technical report for a detailed analysis of QTTB support and resistance levels.
Should I buy Q32 BIO INC (QTTB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of QTTB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of QTTB, evaluating the profitability, health, valuation and growth aspects
- Q32 BIO INC (QTTB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Q32 BIO INC (QTTB) Sales and EPS estimates to see what analysts future expectations are.
- Q32 BIO INC (QTTB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Q32 BIO INC (QTTB) Insider and Institutional Ownership to learn about the owners and their transactions.
- Q32 BIO INC (QTTB) Stock Chart to make your own analysis
- Q32 BIO INC (QTTB) Latest news and press-releases to stay up to date.
Does Q32 BIO INC (QTTB) stock pay dividends?
QTTB does not pay a dividend.
When does Q32 BIO INC (QTTB) report earnings?
Q32 BIO INC (QTTB) will report earnings on 2025-05-08.
What is the Price/Earnings (PE) ratio of Q32 BIO INC (QTTB)?
Q32 BIO INC (QTTB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-18.99).
What is the Short Interest ratio of Q32 BIO INC (QTTB) stock?
The outstanding short interest for Q32 BIO INC (QTTB) is 7.92% of its float. Check the ownership tab for more information on the QTTB short interest.
QTTB Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to QTTB. When comparing the yearly performance of all stocks, QTTB is a bad performer in the overall market: 98.09% of all stocks are doing better.
QTTB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to QTTB. QTTB has a bad profitability rating. Also its financial health evaluation is rather negative.
QTTB Financial Highlights
Over the last trailing twelve months QTTB reported a non-GAAP Earnings per Share(EPS) of -18.99. The EPS increased by 29.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -51.7% | ||
| ROE | -841.11% | ||
| Debt/Equity | 1.68 |
QTTB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to QTTB. The Buy consensus is the average rating of analysts ratings from 10 analysts.